HMTXF

Hemostemix Inc. is a biotechnology firm dedicated to the research, development, and commercialization of stem cell therapies derived from blood, aimed at addressing a range of medical conditions. These innovative treatments are uniquely developed from a patient's own blood, providing a non-invasive source of therapeutic cells. Leading their pipeline is ACP-01, an autologous cell therapy currently undergoing Phase II clinical trials in both Canada and the United States. This product targets critical limb ischemia, along with various heart and peripheral arterial diseases. The company is also actively developing other cellular products, including synergistic cell populations and neural cell precursors. Hemostemix Inc. operates from its headquarters in Calgary, Canada.